Pfizer has three separate patents for Lyrica that were at issue in this case: U.S. Patent No. 6,197,819 covers the active ingredient pregabalin and expires December 30, 2018. U.S. Patent No. RE 41,920 covers methods for using pregabalin to treat pain and expires December 30, 2018.